Mutual of America Capital Management LLC Lowers Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Mutual of America Capital Management LLC trimmed its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 2.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 178,688 shares of the biopharmaceutical company’s stock after selling 5,253 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Halozyme Therapeutics were worth $10,228,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of HALO. GAMMA Investing LLC grew its holdings in shares of Halozyme Therapeutics by 96.6% during the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 254 shares during the last quarter. International Assets Investment Management LLC bought a new position in Halozyme Therapeutics in the 2nd quarter valued at approximately $33,000. Skandinaviska Enskilda Banken AB publ purchased a new stake in Halozyme Therapeutics during the 2nd quarter valued at $49,000. Toth Financial Advisory Corp bought a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth $57,000. Finally, FSC Wealth Advisors LLC purchased a new position in shares of Halozyme Therapeutics in the third quarter worth $65,000. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $45.65 on Monday. The stock’s fifty day moving average is $56.04 and its 200 day moving average is $53.48. Halozyme Therapeutics, Inc. has a one year low of $33.15 and a one year high of $65.53. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. The stock has a market cap of $5.81 billion, a P/E ratio of 15.12, a P/E/G ratio of 0.42 and a beta of 1.29.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. JMP Securities lifted their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Wells Fargo & Company cut shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their price objective for the company from $58.00 to $62.00 in a report on Monday, October 7th. Morgan Stanley lifted their target price on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. JPMorgan Chase & Co. cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price target for the company from $52.00 to $57.00 in a report on Thursday, September 19th. Finally, Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $61.11.

Insider Transactions at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $61.75, for a total transaction of $617,500.00. Following the sale, the senior vice president now directly owns 168,176 shares in the company, valued at $10,384,868. This trade represents a 5.61 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 70,000 shares of company stock valued at $4,042,500 over the last quarter. 2.40% of the stock is currently owned by company insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.